-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93

Benzinga·07/16/2026 20:20:54
语音播报
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.